Autopsy report · NCT02970331

A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis

“FDA requested us to stop the study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Maruho Co., Ltd.

Sponsor type

Industry

Conditions

Psoriasis

Interventions

pefcalcitol ointment, 0.005%

Participants

0

Trials that died the same way

• Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.
  “The study stopped due to marketing approval by the FDA.” (79% match in meaning)
• Safety of SP-420 in the Treatment of Transfusional Iron Overload
  “Study is on hold by FDA in the US.” (75% match in meaning)
• How Can a Driving Virtual Reality Tool Improve Quality of Life and Social Autonomy in Patients With Schizophrenia
  “Decision to stop the study” (72% match in meaning)
• Pre-emptive Anakinra for Cytokine Event Reduction
  “The trial has been stopped pending FDA approval of modifications to the trial protocol.” (72% match in meaning)
• A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease
  “study intervention was approved by the FDA” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.